Jacquelyn W. Chou
Research Subjects
Jacquelyn W. Chou has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Meaghan Roach
PRECISIONheor, Los Angeles, CA
3 shared publications A Simpson
PRECISIONheor , Bethesda , United States of America
1 shared publicationAnupam B. Jena
Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
1 shared publication- Bruce S. Lavin
Bioserenity Inc, Atlanta, USA
1 shared publication - C Williams
PRECISIONheor , Bethesda , United States of America
1 shared publication - Cathy Chen
Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA
1 shared publication
Latest Publications
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Decoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: a targeted literature review
Background: Major bleeding is an adverse event associated with using direct oral anticoagulants (DOACs) for treatment of atrial fibrillation (AF). Incidence rates of major bleeding vary notably between randomised controlled trials (RCTs) and real-world evidence (RWE) studies. This may be attributable to inconsistent major bleeding definitions across RWE studies. RCTs commonly use the International Society on Thrombosis and Haemostasis (ISTH) major bleeding definition, including fatal bleeding, critical area/organ bleeding, bleeding requiring a blood transfusion of 2 or more units, and/or reductions in haemoglobin. These parameters may be absent in RWE studies, leading to utilisation of proxy definitions. Thus, the components used to define major bleeding in RWE studies remain unclear. Purpose: To examine major bleeding definitions via a targeted literature review of retrospective observational studies on patients with AF receiving DOACs in routine clinical practice. Methods: Studies of patients with AF receiving DOACs that were published between 2012 and 2022 were identified using keywords and MeSH terms in PubMed. Retrospective observational studies were screened for inclusion by title and abstract, and subsequently by full text. Articles were assessed for the types of databases and DOAC therapies studied. Components of major bleeding definitions were recorded and compared across database types. Results: Of 328 articles screened, 18 retrospective observational studies were included in this analysis. The most common data sources were claims data (n = 10), followed by electronic medical records (n = 4), and registry data (n = 4). Across studies, major bleeding incidence rates varied from 0.59 to 11.4 events per 100 person-years. Of the 6 components of major bleeding definitions identified, requiring hospitalisation (n = 12) was the most frequent (Figure), though is not essential per the ISTH definition. No articles used fatal bleeding as a component to define major bleeding. Approximately half of all articles used the component involvement of critical organ or site (n = 7). Requiring blood transfusion was used in 6 articles and only 4 used reduction in haemoglobin or haematocrit levels (none of these involved claims data). Conclusions: This targeted literature review of retrospective database studies of routine clinical practice decodes proxy use of ISTH major bleeding definitions. Claims data were the most common data source but lacked components describing fatal bleeding and haemoglobin levels. Further research is vital to assess the variation in reported major bleeding rates in RWE studies using proxy definitions in place of the ISTH definition.Figure
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessDecoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: a targeted literature review
Background: Major bleeding is an adverse event associated with using direct oral anticoagulants (DOACs) for treatment of atrial fibrillation (AF). Incidence rates of major bleeding vary notably between randomised controlled trials (RCTs) and real-world evidence (RWE) studies. This may be attributable to inconsistent major bleeding definitions across RWE studies. RCTs commonly use the International Society on Thrombosis and Haemostasis (ISTH) major bleeding definition, including fatal bleeding, critical area/organ bleeding, bleeding requiring a blood transfusion of 2 or more units, and/or reductions in haemoglobin. These parameters may be absent in RWE studies, leading to utilisation of proxy definitions. Thus, the components used to define major bleeding in RWE studies remain unclear. Purpose: To examine major bleeding definitions via a targeted literature review of retrospective observational studies on patients with AF receiving DOACs in routine clinical practice. Methods: Studies of patients with AF receiving DOACs that were published between 2012 and 2022 were identified using keywords and MeSH terms in PubMed. Retrospective observational studies were screened for inclusion by title and abstract, and subsequently by full text. Articles were assessed for the types of databases and DOAC therapies studied. Components of major bleeding definitions were recorded and compared across database types. Results: Of 328 articles screened, 18 retrospective observational studies were included in this analysis. The most common data sources were claims data (n = 10), followed by electronic medical records (n = 4), and registry data (n = 4). Across studies, major bleeding incidence rates varied from 0.59 to 11.4 events per 100 person-years. Of the 6 components of major bleeding definitions identified, requiring hospitalisation (n = 12) was the most frequent (Figure), though is not essential per the ISTH definition. No articles used fatal bleeding as a component to define major bleeding. Approximately half of all articles used the component involvement of critical organ or site (n = 7). Requiring blood transfusion was used in 6 articles and only 4 used reduction in haemoglobin or haematocrit levels (none of these involved claims data). Conclusions: This targeted literature review of retrospective database studies of routine clinical practice decodes proxy use of ISTH major bleeding definitions. Claims data were the most common data source but lacked components describing fatal bleeding and haemoglobin levels. Further research is vital to assess the variation in reported major bleeding rates in RWE studies using proxy definitions in place of the ISTH definition.Figure
- Open Access
- 12 March 2024
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2024, 1-10
The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
Background. Over the last 25years, clinical practice guidelines have emerged as a means to standardize and improve care. As pharmaceutical innovations develop, guidelines are updated to incorporate new interventions. However, the extent to which pharmacotherapies are represented as treatment options in guideline recommendations has not been well elucidated. This study aimed to quantify the role pharmacotherapy has played in clinical practice guidelines across a range of chronic diseases over the past 20years. Methods. Clinical practice guidelines published from 2000 to 2021 were identified for five chronic diseases: ischemic heart disease (IHD), non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), Alzheimers disease (AD), and type 2 diabetes (T2D). Guidelines were reviewed and data on treatment recommendations were collected, including the type of intervention, line of therapy, and, for pharmacotherapies, year of regulatory approval and year of inclusion in guidelines. Results. In total, 92 clinical practice guidelines were reviewed. Among the 184 discrete recommended interventions across the five disease areas, 146 (79.3) were pharmacotherapies, 21 (11.4) were behavioral modifications, 6 (3.3) were surgical interventions, and 11 (6) were other interventions. Across guidelines, when a line of therapy was specified, behavioral modifications and pharmacotherapies were most frequently recommended as first-line interventions, whereas surgical interventions were more often recommended for subsequent lines of treatment. The time from regulatory approval of novel pharmacotherapies to inclusion in guideline recommendations varied considerably by disease area and geography. Conclusions. Across the reviewed disease areas, behavioral interventions and pharmacotherapies are shown to be critical components of clinical practice. Over the last 20years, novel pharmaceutical innovations have been incorporated into clinical practice guideline recommendations; however, with varying speeds of adoption. Given the increasing pace of pharmacologic innovation, timely updates of clinical practice guidelines are critical to evolving the standard of care and practicing evidence-based medicine.
- 12 March 2024
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2024, 1-10
Open AccessThe Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
Background. Over the last 25years, clinical practice guidelines have emerged as a means to standardize and improve care. As pharmaceutical innovations develop, guidelines are updated to incorporate new interventions. However, the extent to which pharmacotherapies are represented as treatment options in guideline recommendations has not been well elucidated. This study aimed to quantify the role pharmacotherapy has played in clinical practice guidelines across a range of chronic diseases over the past 20years. Methods. Clinical practice guidelines published from 2000 to 2021 were identified for five chronic diseases: ischemic heart disease (IHD), non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), Alzheimers disease (AD), and type 2 diabetes (T2D). Guidelines were reviewed and data on treatment recommendations were collected, including the type of intervention, line of therapy, and, for pharmacotherapies, year of regulatory approval and year of inclusion in guidelines. Results. In total, 92 clinical practice guidelines were reviewed. Among the 184 discrete recommended interventions across the five disease areas, 146 (79.3) were pharmacotherapies, 21 (11.4) were behavioral modifications, 6 (3.3) were surgical interventions, and 11 (6) were other interventions. Across guidelines, when a line of therapy was specified, behavioral modifications and pharmacotherapies were most frequently recommended as first-line interventions, whereas surgical interventions were more often recommended for subsequent lines of treatment. The time from regulatory approval of novel pharmacotherapies to inclusion in guideline recommendations varied considerably by disease area and geography. Conclusions. Across the reviewed disease areas, behavioral interventions and pharmacotherapies are shown to be critical components of clinical practice. Over the last 20years, novel pharmaceutical innovations have been incorporated into clinical practice guideline recommendations; however, with varying speeds of adoption. Given the increasing pace of pharmacologic innovation, timely updates of clinical practice guidelines are critical to evolving the standard of care and practicing evidence-based medicine.
- 1 December 2023
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 29 (12) , 696-703
Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
Objectives: To estimate the comprehensive value of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) compared with peginterferon alfa and ribavirin (PEG/riba) employing a generalized cost-effectiveness analysis (GCEA). Study Design: To assess the societal-level cost-effectiveness of DAA treatment for HCV, we extended a previously published discrete-time Markov simulation model of HCV transmission and progression to include market dynamics and broader elements of value. Methods: We followed a stepwise process to add novel value elements to a traditional CEA model for HCV treatments. For each additional element of value, we estimated incremental cost-effectiveness ratios (ICERs) of DAAs compared with PEG/riba. Results: The health technology assessment (HTA)–style model yielded an ICER value of $64,512 per quality-adjusted life-year (QALY). Adding transmission dynamics resulted in an ICER value of $52,971 per QALY, whereas accounting for transmission dynamics and dynamic price and efficacy further decreased ICER values by 90% to $6406 per QALY. Incorporating genericization, productivity loss, caregiver spillover, and differential valuations of LYs vs quality of life, disease severity, and insurance value further decreased the ICER value to $4487 per QALY, a 93% reduction from the baseline HTA-style CEA to the fully realized GCEA. Conclusions: Our GCEA study results confirm that DAAs are a cost-effective treatment for HCV compared with PEG/riba even when using conventional cost-effectiveness approaches. Incorporating broader elements of value resulted in more than a 10-fold improvement in cost-effectiveness, emphasizing the substantive impact of a generalized approach and the importance of incorporating GCEAs into decision-making.
- 1 December 2023
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 29 (12) , 696-703
Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
Objectives: To estimate the comprehensive value of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) compared with peginterferon alfa and ribavirin (PEG/riba) employing a generalized cost-effectiveness analysis (GCEA). Study Design: To assess the societal-level cost-effectiveness of DAA treatment for HCV, we extended a previously published discrete-time Markov simulation model of HCV transmission and progression to include market dynamics and broader elements of value. Methods: We followed a stepwise process to add novel value elements to a traditional CEA model for HCV treatments. For each additional element of value, we estimated incremental cost-effectiveness ratios (ICERs) of DAAs compared with PEG/riba. Results: The health technology assessment (HTA)–style model yielded an ICER value of $64,512 per quality-adjusted life-year (QALY). Adding transmission dynamics resulted in an ICER value of $52,971 per QALY, whereas accounting for transmission dynamics and dynamic price and efficacy further decreased ICER values by 90% to $6406 per QALY. Incorporating genericization, productivity loss, caregiver spillover, and differential valuations of LYs vs quality of life, disease severity, and insurance value further decreased the ICER value to $4487 per QALY, a 93% reduction from the baseline HTA-style CEA to the fully realized GCEA. Conclusions: Our GCEA study results confirm that DAAs are a cost-effective treatment for HCV compared with PEG/riba even when using conventional cost-effectiveness approaches. Incorporating broader elements of value resulted in more than a 10-fold improvement in cost-effectiveness, emphasizing the substantive impact of a generalized approach and the importance of incorporating GCEAs into decision-making.
- 1 June 2020
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 131 (11) , 1058-1065
Challenges and opportunities in insomnia disorder
Insomnia disorder is a prevalent, often unrecognized condition that affects millions. This clinical disorder is characterized by difficulty initiating or maintaining sleep over a sustained period. In fact, insomnia disorder affects much more than sleep; it increases the risk for developing serious medical and psychiatric comorbidities and can exacerbate existing conditions. The association between insomnia disorder and serious medical and psychiatric comorbidities are complex and directionality is not yet fully understood. There remain gaps in the treatment landscape for insomnia disorder. We performed a narrative review of the published literature to identify challenges, unmet needs, and burden associated with insomnia disorder. In this paper, we describe the substantial burden that insomnia disorder poses on patients, the healthcare system, and society in the U.S. This paper explores the factors attributable to this burden including limited provider knowledge, inadequate treatment options, and unknown long-term impacts of off-label treatments. Several recommendations are proposed to address these challenges and improve patient outcomes through efforts to: (1) establish the societal value of treatment; (2) improve the clinical understanding of insomnia disorder; and (3) prioritize development of and access to effective treatments that do not pose addiction potential or tolerability issues.
- 1 June 2020
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 131 (11) , 1058-1065
Challenges and opportunities in insomnia disorder
Insomnia disorder is a prevalent, often unrecognized condition that affects millions. This clinical disorder is characterized by difficulty initiating or maintaining sleep over a sustained period. In fact, insomnia disorder affects much more than sleep; it increases the risk for developing serious medical and psychiatric comorbidities and can exacerbate existing conditions. The association between insomnia disorder and serious medical and psychiatric comorbidities are complex and directionality is not yet fully understood. There remain gaps in the treatment landscape for insomnia disorder. We performed a narrative review of the published literature to identify challenges, unmet needs, and burden associated with insomnia disorder. In this paper, we describe the substantial burden that insomnia disorder poses on patients, the healthcare system, and society in the U.S. This paper explores the factors attributable to this burden including limited provider knowledge, inadequate treatment options, and unknown long-term impacts of off-label treatments. Several recommendations are proposed to address these challenges and improve patient outcomes through efforts to: (1) establish the societal value of treatment; (2) improve the clinical understanding of insomnia disorder; and (3) prioritize development of and access to effective treatments that do not pose addiction potential or tolerability issues.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Research and Reviews in Parkinsonism
- Vol. ume 10, 1-6
Challenges and Opportunities in Atypical Parkinsonian Syndromes: Call to Action
Neurodegenerative diseases are a leading cause of disability and death in the United States, and the burden of rare neurodegenerative conditions such as atypical Parkinsonian syndromes is expected to grow in the coming years as the size of the older population increases at an unprecedented rate. Atypical Parkinsonian syndromes encompass a collective of rare neurodegenerative diseases that are often misdiagnosed as Parkinson’s disease due to similar signs and symptoms. These syndromes include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD), and are characterized by rapid disease progression and decreased life expectancy. In this paper, we describe the substantial burden atypical Parkinsonian syndromes pose to the healthcare system and patients attributable to challenges in diagnosis, ineffective treatment options, and rapid functional decline. Despite increased understanding and recognition of these disorders, there remains significant unmet need for patients with atypical Parkinsonian syndromes. We provide recommendations to policymakers to support access to effective disease management of atypical Parkinsonian syndromes through legislative efforts that i) prioritize development of disease-modifying treatments, ii) focus on objectively assessing disease progression in addition to symptom management, and iii) bring forth economic frameworks that capture the full value of treatments.
- 1 January 2020
- Published by Taylor & Francis in Research and Reviews in Parkinsonism
- Vol. ume 10, 1-6
Open AccessChallenges and Opportunities in Atypical Parkinsonian Syndromes: Call to Action
Neurodegenerative diseases are a leading cause of disability and death in the United States, and the burden of rare neurodegenerative conditions such as atypical Parkinsonian syndromes is expected to grow in the coming years as the size of the older population increases at an unprecedented rate. Atypical Parkinsonian syndromes encompass a collective of rare neurodegenerative diseases that are often misdiagnosed as Parkinson’s disease due to similar signs and symptoms. These syndromes include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD), and are characterized by rapid disease progression and decreased life expectancy. In this paper, we describe the substantial burden atypical Parkinsonian syndromes pose to the healthcare system and patients attributable to challenges in diagnosis, ineffective treatment options, and rapid functional decline. Despite increased understanding and recognition of these disorders, there remains significant unmet need for patients with atypical Parkinsonian syndromes. We provide recommendations to policymakers to support access to effective disease management of atypical Parkinsonian syndromes through legislative efforts that i) prioritize development of disease-modifying treatments, ii) focus on objectively assessing disease progression in addition to symptom management, and iii) bring forth economic frameworks that capture the full value of treatments.
- Open Access
- 28 February 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 140
Short-term budget affordability of hepatitis C treatments for state Medicaid programs
With some Medicaid state programs still restricting patient access to hepatitis C (HCV) treatment, it is important to demonstrate how states could expand treatment access to a broader Medicaid population and balance short-term budget concerns. We used the HCV Transmission and Progression (TaP) Markov model to quantify the impact of removing restrictions to HCV treatment access on the infected populations, expenditures, and net social value for the North Carolina (NC), Oregon (OR), and Wisconsin (WI) Medicaid programs. Four HCV treatment access scenarios were modeled: 1) Baseline: Patients were treated according to Medicaid disease severity and sobriety requirements in 2015; 2) Remove Sobriety Restrictions: Disease severity restrictions were maintained, but people who inject drugs (PWID) were given access to treatment; 3) Treat Early: All patients, except for PWIDs, regardless of disease severity, were eligible for treatment and the diagnosis rate increased from 50 to 66%; and 4) Remove Access Restrictions: all patients, regardless of disease severity and sobriety, were eligible for treatment. Our key model outputs were: number of infected Medicaid beneficiaries, HCV-related medical and treatment expenditures, total social value, and state Medicaid spending over 10 years. Across all three states, removing access restrictions resulted in the greatest benefits over 10 years (net social value relative to baseline = $408 M in NC; $408 M in OR; $271 M in WI) and the smallest infected population (5200 in NC; 2000 in OR; 614 in WI). Reduced disease transmission resulted in lower health care expenditures (-$66 M in NC; -$50 M in OR; -$54 M in WI). All of the expanded treatment access policies achieved break-even costs—where total treatment and health care expenditures fell below those of Baseline—in 4 to 8 years. Removing access restrictions yielded the greatest improvement in social value (net of medical expenditures and treatment costs, QALYs valued at $150 K per QALY). While increasing treatment access in Medicaid will raise short-term costs, it will also provide clear benefits relatively quickly by saving money and improving health within a 10-year window. Patients and taxpayers would benefit by considering these gains and taking a more expansive and long-term view of HCV treatment policies.
- 28 February 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 140
Open AccessShort-term budget affordability of hepatitis C treatments for state Medicaid programs
With some Medicaid state programs still restricting patient access to hepatitis C (HCV) treatment, it is important to demonstrate how states could expand treatment access to a broader Medicaid population and balance short-term budget concerns. We used the HCV Transmission and Progression (TaP) Markov model to quantify the impact of removing restrictions to HCV treatment access on the infected populations, expenditures, and net social value for the North Carolina (NC), Oregon (OR), and Wisconsin (WI) Medicaid programs. Four HCV treatment access scenarios were modeled: 1) Baseline: Patients were treated according to Medicaid disease severity and sobriety requirements in 2015; 2) Remove Sobriety Restrictions: Disease severity restrictions were maintained, but people who inject drugs (PWID) were given access to treatment; 3) Treat Early: All patients, except for PWIDs, regardless of disease severity, were eligible for treatment and the diagnosis rate increased from 50 to 66%; and 4) Remove Access Restrictions: all patients, regardless of disease severity and sobriety, were eligible for treatment. Our key model outputs were: number of infected Medicaid beneficiaries, HCV-related medical and treatment expenditures, total social value, and state Medicaid spending over 10 years. Across all three states, removing access restrictions resulted in the greatest benefits over 10 years (net social value relative to baseline = $408 M in NC; $408 M in OR; $271 M in WI) and the smallest infected population (5200 in NC; 2000 in OR; 614 in WI). Reduced disease transmission resulted in lower health care expenditures (-$66 M in NC; -$50 M in OR; -$54 M in WI). All of the expanded treatment access policies achieved break-even costs—where total treatment and health care expenditures fell below those of Baseline—in 4 to 8 years. Removing access restrictions yielded the greatest improvement in social value (net of medical expenditures and treatment costs, QALYs valued at $150 K per QALY). While increasing treatment access in Medicaid will raise short-term costs, it will also provide clear benefits relatively quickly by saving money and improving health within a 10-year window. Patients and taxpayers would benefit by considering these gains and taking a more expansive and long-term view of HCV treatment policies.